Menu
MapConnectionsTopicsBulgariaThe Night (K-TRIO)Marie Skłodowska-CurieFor studentsFor teachersMethodologySurprise me
H2020Doctoral network2015–2019

ANTIVIRALS · European Training Network on Antiviral Drug Development

Horizon 2020 — Marie Skłodowska-Curie Actions

Duration
2015-03-01 → 2019-09-30
EU contribution
€3,837,214
Participants
13
Scheme
MSCA-ITN-ETN

Lines connect the coordinator with its partners. CORDIS does not always give exact coordinates for projects before 2014. These points are placed at city or country level.

Results in brief

European Training Network on Antiviral Drug Development

Viral infections are a major cause of disease, with enormous costs in morbidity/mortality and economic losses worldwide. Since only a few viral diseases can currently be prevented by vaccination, antiviral therapy is an essential instrument to control virus infections. Antiviral therapies are available for only a few diseases, leading to a great unmet medical need for antiviral drugs to treat or prevent infections with many important human pathogens. In line with this, there is great need for experts in the field which have been trained in a multidisciplinary and intersectoral setting, with attention for both basic and applied aspects of antiviral drug development. The ANTIVIRALS consortium, consisting of 7 academic and 3 industrial leaders in the field, implemented a research, training and dissemination programme to educate these experts, to advance the field and to create a basis for further use of the results.

Data: CORDIS, © European Union

Project objective

Viral infections are a major cause of disease, mortality and economic losses worldwide. Antiviral therapy is an essential instrument to control virus infections. At present, however, licensed antiviral drugs have been developed only against a limited number of viruses (e.g. HIV, HCV, influenza, herpesviruses). There is a clear and unmet need for antiviral drugs to treat infections with other important human pathogens.Europe needs well-trained experts with multidisciplinary skills to advance the antiviral drug development field. However, few, if any, European universities or research institutes have the ability to deliver an intersectoral training programme that covers the broad spectrum of disciplines important for antiviral drug development.The ANTIVIRALS partnership has been established to fill this gap. It consists of six outstanding European academic partners and four industrial partners (two large R&D companies, of which one is specialized in antiviral drug discovery and development, and two SMEs), and two partner organisations (incl. one SME specialised in education). All partners are leaders in their field, ensuring state-of-the-art training possibilities, and their skills are highly complementary.ANTIVIRALS aims to introduce 15 ESRs to state-of-the-art knowledge and technology applied in antiviral drug development through both local and network-wide training activities. Individual research projects, research training workshops and intersectoral secondments will be supplemented with complementary skills courses and dissemination activities to improve career development and perspectives. The industrial partners are actively involved in the entire programme and will organize an industry-oriented conference aimed at further bridging the gap between academia and industry. Thus, ANTIVIRALS offers talented researchers a multidisciplinary and intersectoral training programme and prepares them for a future leading role in antiviral drug development in Europe.

Original text from CORDIS.

Participants

  • UNIVERSITEIT UTRECHT · UtrechtCoordinatorNetherlands
  • ACADEMISCH ZIEKENHUIS LEIDEN · LeidenNetherlands
  • AICURIS GMBH & CO. KG · WUPPERTALGermany
  • ARATANA THERAPEUTICS NV · HEVERLEEBelgium
  • CARDIFF UNIVERSITY · CARDIFFUnited Kingdom
  • COMPLIX LUXEMBOURG SA · LUXEMBOURGCity levelLuxembourg
  • COMPLIX NV · DIEPENBEEKCity levelBelgium
  • KATHOLIEKE UNIVERSITEIT LEUVEN · LeuvenBelgium
  • UNIVERSITAT WIEN · WienAustria
  • UNIVERSITATSKLINIKUM HEIDELBERG · HeidelbergGermany
  • UNIVERSITE D'AIX MARSEILLE · MarseilleFrance
  • VIROVET · LEUVENBelgium
  • Virology Education B.V. · UtrechtNetherlands

Links

Data: CORDIS, © European Union